Lilly Dermatology Data at Fall Clinical 2026: EBGLYSS, Psoriasis Biomarkers and Pediatric Alopecia Areata

Eli Lilly and Company is bringing 21 dermatology poster presentations to the 2026 Fall Clinical Dermatology Conference, placing treatment durability, biomarker research and pediatric outcomes at the center of its latest clinical research activity. The presentations cover atopic dermatitis, psoriasis and alopecia areata, three chronic conditions that continue to shape pharmaceutical research and treatment development.

The programme highlights EBGLYSS (lebrikizumab), research from the TOGETHER-PsO study involving Taltz (ixekizumab) and Zepbound (tirzepatide) and long-term findings for Olumiant (baricitinib) in pediatric patients with severe alopecia areata. Together, these studies reflect the industry's growing interest in sustained disease control, treatment experience and the biological relationships between inflammatory skin conditions and other health factors.

For pharmaceutical manufacturers, ingredient suppliers and procurement teams, the research also provides a useful view of the therapies and development programmes attracting attention in dermatology. Clinical progress can influence future manufacturing requirements, research investment and the longer-term sourcing needs of the pharmaceutical supply chain.

Lilly's 21 Dermatology Posters Highlight Three Research Priorities

Lilly's presentation programme at the Fall Clinical Dermatology Conference, held from October 8 to 11, 2026, in Las Vegas, brings together research across several patient populations and treatment approaches.

The programme focuses on three broad areas:

• Atopic dermatitis: Thirteen posters examine EBGLYSS, including sustained disease control, maintenance dosing, topical treatment use and clinical findings in different patient groups.

• Psoriasis and metabolic health: Six presentations examine the concomitant use of Taltz and Zepbound, including exploratory biomarker analysis from the TOGETHER-PsO study.

• Pediatric alopecia areata: Research from the BRAVE-AA-PEDS clinical trial examines long-term outcomes with Olumiant in patients aged 12 years and older with severe alopecia areata.

This distribution demonstrates the breadth of Lilly's dermatology portfolio. Rather than concentrating on one medicine or condition, the company is examining treatment performance, patient experience and biological mechanisms across multiple areas of immune-mediated disease.

For the pharmaceutical sector, this research mix matters because each programme follows a different development pathway. Biologic medicines, targeted therapies and oral treatments can require distinct manufacturing processes, quality controls and commercial supply arrangements.

EBGLYSS Research Examines Long-Term Atopic Dermatitis Control

Atopic dermatitis is a chronic inflammatory skin condition that can cause persistent itching, irritation and recurring flare-ups. Treatment research increasingly examines not only whether a medicine improves symptoms but also how consistently patients maintain those improvements over time.

Lilly's EBGLYSS programme addresses these questions through 13 poster presentations focused on lebrikizumab, a monoclonal antibody that selectively targets interleukin-13, or IL-13. This signalling pathway plays an important role in the inflammatory processes associated with atopic dermatitis.

The presentations explore several practical aspects of treatment:

• Durability of response: Researchers are examining whether patients maintain disease control over extended treatment periods and experience fewer flare-ups.

• Maintenance dosing: Adolescent data examine whether an eight-week maintenance schedule can sustain treatment response in appropriate patients.

• Topical treatment requirements: The programme considers whether effective systemic treatment can reduce the need for additional topical therapies.

• Different patient populations: Research includes adolescents, adults and investigational pediatric findings, as well as patients whose condition affects areas such as the hands and feet.

These research questions reflect a wider industry focus on treatment consistency and practical disease management. A medicine's long-term performance can influence how clinicians evaluate its role within treatment plans and how healthcare systems assess its potential value.

The programme also includes real-world evidence on treatment persistence and research involving patients with other atopic conditions. Such studies can help researchers understand how clinical trial findings translate into routine healthcare settings.

TOGETHER-PsO Investigates the Connection Between Psoriasis and Metabolic Health

Psoriasis is an immune-mediated inflammatory disease that affects the skin and can occur alongside other health conditions. Research into its relationship with obesity and metabolic health is gaining attention because these factors may interact in ways that affect disease management.

Lilly's TOGETHER-PsO research examines the use of Taltz, an ixekizumab-based treatment, alongside Zepbound, which contains tirzepatide, in adults with moderate-to-severe plaque psoriasis who also have overweight or obesity and at least one weight-related comorbidity.

Six conference presentations examine this treatment combination. One key area involves exploratory biomarker analysis designed to provide deeper insight into the immunometabolic biology connecting psoriasis and obesity.

Biomarkers can help researchers investigate biological processes associated with disease activity and treatment response. In this setting, the analysis aims to improve understanding of how metabolic factors and inflammatory pathways may interact.

The study's research direction has several important implications:

• Broader treatment research: Investigators can examine how different therapeutic approaches may address interconnected health factors rather than evaluating a skin condition in isolation.

• More detailed biological evidence: Biomarker studies can help researchers identify patterns that support future research questions and clinical investigation.

• Complex treatment planning: Research involving multiple medicines raises questions about patient selection, treatment coordination and the evidence needed to support clinical decisions.

These findings should be understood within the scope of the study. Exploratory biomarker analysis can generate valuable scientific insights, but it does not automatically establish a causal relationship or prove that a combination treatment will benefit every patient.

For pharmaceutical developers, the programme illustrates the importance of research that connects clinical outcomes with underlying biological mechanisms. It also shows how therapeutic development increasingly intersects with research into obesity and other metabolic conditions.

Olumiant Data Focus on Pediatric Alopecia Areata

Alopecia areata is an autoimmune condition that causes hair loss and can have a substantial effect on quality of life. Severe disease in children and adolescents presents particular treatment challenges, making age-specific clinical evidence an important part of pharmaceutical development.

Lilly's programme includes long-term findings from the BRAVE-AA-PEDS Phase 3 clinical trial, which evaluates Olumiant (baricitinib) in pediatric patients aged 12 years and older with severe alopecia areata.

The trial was specifically designed to investigate treatment in this population. The conference programme highlights sustained efficacy and safety findings over extended follow-up periods.

Long-term research is important because an initial treatment response provides only part of the information clinicians need. Researchers must also assess how benefits persist, how patients tolerate treatment and what safety findings emerge as exposure continues.

The pediatric focus also highlights the need to develop evidence for distinct age groups rather than assuming that findings from adults automatically apply to younger patients. Clinical programmes designed for children and adolescents can help address these evidence gaps.

For the pharmaceutical industry, this work reinforces the importance of carefully structured trials, consistent product quality and ongoing safety monitoring. These requirements influence development timelines, clinical supply planning and the documentation needed to support regulated medicine production.

What the Clinical Findings Mean for Pharmaceutical Manufacturing and Supply Chains

Clinical conference presentations do not immediately translate into new commercial orders. However, sustained research activity can help industry participants understand which therapeutic areas may continue to attract investment and which manufacturing capabilities could become strategically important.

Lilly's dermatology programme spans monoclonal antibodies, other targeted therapies and oral medicines. Each category has its own production requirements, quality systems and supply-chain considerations.

Biologic medicines such as lebrikizumab require specialised manufacturing processes and rigorous control of product characteristics. Their production can involve cell culture, purification, formulation and cold-chain handling, depending on the product and its approved distribution requirements.

Small-molecule medicines follow different production pathways. Manufacturers must manage chemical synthesis, impurity profiles, formulation consistency and applicable pharmaceutical quality standards.

For procurement teams and suppliers, the wider implications include:

• Raw material planning: Pharmaceutical manufacturers need dependable sources of suitable starting materials, excipients, solvents and processing inputs for their respective production platforms.

• Quality assurance: Suppliers must provide appropriate documentation, traceability and evidence that materials meet agreed specifications.

• Supply continuity: Manufacturers need to assess lead times, supplier capacity and contingency arrangements for critical inputs.

• Regulatory alignment: Material sourcing must support applicable good manufacturing practice requirements and product-specific quality obligations.

The clinical programmes discussed at Fall Clinical do not establish a direct demand forecast for any individual chemical or excipient. Instead, they offer a broader view of the research activity supporting dermatology medicines and the specialised supply networks that enable pharmaceutical development.

How Pharmaceutical Buyers Can Prepare for Evolving Dermatology Demand

Procurement professionals can use developments in clinical research to strengthen market awareness without treating conference results as immediate purchasing signals. A disciplined approach links scientific developments with actual production plans, regulatory requirements and supplier capabilities.

The first priority is to understand the stage of each programme. Established medicines, ongoing clinical trials and exploratory biomarker studies have different implications for manufacturing volumes and commercial planning.

Buyers should also distinguish between biologic and small-molecule supply chains. A company producing monoclonal antibodies may require specialised biological production inputs, while a conventional pharmaceutical formulation manufacturer may prioritise different chemical ingredients and excipients.

Several practical steps can help purchasing teams respond effectively:

• Review supplier qualifications: Confirm quality credentials, manufacturing capabilities and documentation requirements before onboarding a new supplier.

• Assess material criticality: Identify inputs that could interrupt production if shortages occur, then establish suitable backup sourcing arrangements where feasible.

• Coordinate with technical teams: Engage quality assurance, regulatory affairs and manufacturing colleagues before approving material substitutions or alternative suppliers.

• Monitor development milestones: Follow trial results, regulatory decisions and commercial expansion plans to distinguish emerging opportunities from established demand.

• Evaluate total sourcing risk: Compare suppliers based on consistency, delivery reliability and compliance as well as price.

These steps support more resilient sourcing decisions across pharmaceutical manufacturing. They also help buyers avoid unnecessary inventory commitments based solely on preliminary research announcements.

The Outlook for Dermatology Innovation and Pharmaceutical Buyers

Lilly's 21 presentations at Fall Clinical 2026 highlight how dermatology research now extends beyond initial efficacy assessments. Treatment durability, long-term safety, patient-specific outcomes and the relationship between inflammatory disease and metabolic health all feature in the programme.

EBGLYSS research addresses sustained disease control in atopic dermatitis, while TOGETHER-PsO investigates biological links between psoriasis and metabolic health. Olumiant research adds a pediatric perspective through long-term investigation of severe alopecia areata.

Together, these programmes illustrate the range of scientific questions shaping pharmaceutical research. They also underline the importance of reliable manufacturing, qualified material suppliers and careful procurement planning as medicines progress through development and commercial use.

For chemical traders and pharmaceutical buyers, the most useful response is to monitor the evidence, understand the requirements of each production platform and maintain sourcing strategies that prioritise quality and continuity.